WO2021036896A1 - 一种植物提取方法 - Google Patents
一种植物提取方法 Download PDFInfo
- Publication number
- WO2021036896A1 WO2021036896A1 PCT/CN2020/110179 CN2020110179W WO2021036896A1 WO 2021036896 A1 WO2021036896 A1 WO 2021036896A1 CN 2020110179 W CN2020110179 W CN 2020110179W WO 2021036896 A1 WO2021036896 A1 WO 2021036896A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mulberry
- resin
- extract
- content
- plant
- Prior art date
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 88
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 238
- 239000011347 resin Substances 0.000 claims abstract description 150
- 229920005989 resin Polymers 0.000 claims abstract description 150
- 238000001556 precipitation Methods 0.000 claims abstract description 53
- 238000000926 separation method Methods 0.000 claims abstract description 51
- 150000001450 anions Chemical class 0.000 claims abstract description 48
- 150000001768 cations Chemical class 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 9
- 239000008103 glucose Substances 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 230000000968 intestinal effect Effects 0.000 claims abstract description 4
- 230000002159 abnormal effect Effects 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- 230000001105 regulatory effect Effects 0.000 claims abstract description 3
- 201000010099 disease Diseases 0.000 claims abstract 2
- 240000000249 Morus alba Species 0.000 claims description 163
- 235000008708 Morus alba Nutrition 0.000 claims description 159
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 78
- 125000002091 cationic group Chemical group 0.000 claims description 67
- 239000000419 plant extract Substances 0.000 claims description 67
- 239000007788 liquid Substances 0.000 claims description 62
- 239000000287 crude extract Substances 0.000 claims description 56
- 241000196324 Embryophyta Species 0.000 claims description 54
- 239000002253 acid Substances 0.000 claims description 26
- 239000003957 anion exchange resin Substances 0.000 claims description 24
- 239000003729 cation exchange resin Substances 0.000 claims description 24
- 239000002994 raw material Substances 0.000 claims description 21
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 20
- -1 styrene propylene cation exchange resin Chemical compound 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 230000002378 acidificating effect Effects 0.000 claims description 16
- 239000003480 eluent Substances 0.000 claims description 13
- 235000006437 Morus alba var alba Nutrition 0.000 claims description 12
- 240000001832 Morus alba var. alba Species 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 11
- 125000000129 anionic group Chemical group 0.000 claims description 10
- 241001633583 Adenophora Species 0.000 claims description 7
- 241000233838 Commelina Species 0.000 claims description 7
- 241001632576 Hyacinthus Species 0.000 claims description 7
- 241000218231 Moraceae Species 0.000 claims description 7
- 241000334246 Morus mongolica Species 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 240000009253 Morus australis Species 0.000 claims description 4
- 235000006723 Morus australis Nutrition 0.000 claims description 4
- 241000334254 Morus x mizuho Species 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- 241001632578 Hyacinthus orientalis Species 0.000 claims description 3
- 241000218213 Morus <angiosperm> Species 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 241000208671 Campanulaceae Species 0.000 claims description 2
- 241000037488 Coccoloba pubescens Species 0.000 claims description 2
- 241000233833 Commelinaceae Species 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 241000234280 Liliaceae Species 0.000 claims description 2
- 235000004839 Morus alba var multicaulis Nutrition 0.000 claims description 2
- 244000293610 Morus bombycis Species 0.000 claims description 2
- 235000006721 Morus bombycis Nutrition 0.000 claims description 2
- 241000301123 Morus cathayana Species 0.000 claims description 2
- 235000013382 Morus laevigata Nutrition 0.000 claims description 2
- 244000101211 Morus macroura Species 0.000 claims description 2
- 241000409625 Morus notabilis Species 0.000 claims description 2
- 241001058141 Morus serrata Species 0.000 claims description 2
- 241000334256 Morus wittiorum Species 0.000 claims description 2
- 241000574810 Morus yunnanensis Species 0.000 claims description 2
- 244000184734 Pyrus japonica Species 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 119
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 67
- 238000000034 method Methods 0.000 abstract description 61
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 90
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- 238000003756 stirring Methods 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 229930013930 alkaloid Natural products 0.000 description 40
- 239000012528 membrane Substances 0.000 description 37
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 30
- 229910052793 cadmium Inorganic materials 0.000 description 28
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 28
- 238000010828 elution Methods 0.000 description 27
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 26
- 229910052753 mercury Inorganic materials 0.000 description 26
- 239000006228 supernatant Substances 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 229930003935 flavonoid Natural products 0.000 description 22
- 150000002215 flavonoids Chemical class 0.000 description 22
- 235000017173 flavonoids Nutrition 0.000 description 22
- 229920001282 polysaccharide Polymers 0.000 description 22
- 239000005017 polysaccharide Substances 0.000 description 22
- 229910052785 arsenic Inorganic materials 0.000 description 21
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 21
- 150000004676 glycans Chemical class 0.000 description 21
- 230000005484 gravity Effects 0.000 description 21
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 20
- 150000002500 ions Chemical class 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 238000011068 loading method Methods 0.000 description 18
- 239000012535 impurity Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 15
- 238000010992 reflux Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000003929 acidic solution Substances 0.000 description 11
- 239000012670 alkaline solution Substances 0.000 description 10
- 229910021529 ammonia Inorganic materials 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000001728 nano-filtration Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000010949 copper Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 150000003797 alkaloid derivatives Chemical class 0.000 description 8
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 8
- CGFYHILWFSGVJS-UHFFFAOYSA-N silicic acid;trioxotungsten Chemical compound O[Si](O)(O)O.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 CGFYHILWFSGVJS-UHFFFAOYSA-N 0.000 description 8
- 239000012085 test solution Substances 0.000 description 8
- 238000001471 micro-filtration Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000005374 membrane filtration Methods 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007981 phosphate-citrate buffer Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 241000233839 Commelina communis Species 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 2
- DTOUWTJYUCZJQD-UJERWXFOSA-N Forsythiaside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O)[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O1 DTOUWTJYUCZJQD-UJERWXFOSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940023913 cation exchange resins Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 235000001459 whitebark Nutrition 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- PSGURCKLYDAIEJ-UHFFFAOYSA-N CC(C(C(OCC1C2=CC=CC=C2C2=CC=CC=C12)=O)Cl)=O Chemical compound CC(C(C(OCC1C2=CC=CC=C2C2=CC=CC=C12)=O)Cl)=O PSGURCKLYDAIEJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- DTOUWTJYUCZJQD-QJDQKFITSA-N Forsythiaside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O DTOUWTJYUCZJQD-QJDQKFITSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- RLJMLMKIBZAXJO-UHFFFAOYSA-N lead nitrate Chemical compound [O-][N+](=O)O[Pb]O[N+]([O-])=O RLJMLMKIBZAXJO-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009366 sericulture Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Definitions
- the cationic resin is selected from one or a combination of strong acid cation exchange resins, weak acid cation exchange resins, and strong basic quaternary ammonium cation exchange resins.
- the present invention provides a food, health product or drink, characterized in that the food, health product or drink contains the above-mentioned plant extracts and optional auxiliary materials acceptable on the food, health product or drink .
- Use 732 type strong acid styrene cationic resin 5g to pack the column use 2.5mol/L hydrochloric acid solution to wash until the eluate pH is 3.5; use 1.5mol/L sodium hydroxide solution to wash until the eluate pH is 8.0; 2.5 Wash with mol/L hydrochloric acid solution until the pH of the eluate is 3.5; then rinse with 3 times the column volume of deionized water to complete the activation. Load the concentrated extract, and then use 3L 0.1mol/L ammonia to elute, the elution rate is 10BV/h, and the eluate is collected when the pH of the cation column effluent is >7. When the collection reaches 1L, Stop the collection and pass the collected liquid directly to the anion column for purification.
- the collected liquid obtained after separation by the cation column is thermally concentrated, and the specific gravity of the concentrated liquid is 1.3, which is transferred to the alcohol precipitation tank, and 25 g of anhydrous ethanol is added at 600 rpm of the stirring blade. After the addition of ethanol, the stirring was stopped, the alcohol was precipitated for 24 hours, the supernatant was taken, and concentrated under reduced pressure to obtain the extract extract.
- Example 3 there is no concentration step after the resin is separated and before the alcohol precipitation. Compared with Example 3, the content of heavy metals is increased, and the amount of ethanol is increased by 8 times.
- the content of 1-DNJ is 55%.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (15)
- 一种植物提取方法,其特征在于,包括以下步骤:步骤1):制备植物粗提液;步骤2):所述粗提液经阳离子树脂和任选的阴离子树脂分离,得到收集液;步骤3):对步骤2)得到的收集液进行浓缩处理;步骤4):对步骤3)得到的浓缩液进行醇沉处理;任选的步骤5)浓缩干燥处理。
- 根据权利要求1所述的提取方法,其特征在于,所述植物为桑科(Moraceae)、百合科(Liliaceae)、桔梗科(Campanulaceae)、鸭跖草科(Commelinaceae)植物;优选地,所述植物为桑属(Morus)、风信子属(Hyacinthus)、沙参属(Adenophora)、鸭跖草属(Commelina)植物;优选地,所述植物为鲁桑(Morus multicaulis Perrott.)、白桑(Morus alba L.)、广东桑(Morus atropurpurea Roxb)、瑞穗桑(Morusmizuho Hotta)、长穗桑(Morus wittiorum Hand Mazz.)、长果桑(Morus laevigata Wall)、黑桑(Morus nigra Linn.)、华桑(Morus cathayana Hemsi.)、细齿桑(Morus serrata Roxb.)、蒙桑(Morus mongolica Schneid.)、山桑(Morus bombycis Koidz.)、川桑(Morus notabilis Schneid.)、唐鬼桑(Morus nigriformis Koidz.)、滇桑(Morusyunnanensis Koidz.)、鸡桑(Morus australis Poir.)、鬼桑(Morus mongolica(Bur.)Schneid var.diabolica Koidz.)、大叶桑、垂枝桑(Morus alba Var.Pendula Dippel)、白脉桑及用以上桑种育成的桑树品种、以上桑种的种内或种间选育的杂交桑,以及风信子(Hyacinthus orientalis)、沙参(Adenophora.triphylla var.japonica)、鸭跖草(Commelina communi)中的任意一种或多种的组合;优选地,所述植物选自广东桑、鲁桑、白桑、细齿桑、山桑或杂交桑,所述杂交桑优选为粤桑11号、桂桑优62号或桑特优2号。
- 根据权利要求1或2所述的提取方法,其特征在于,所述提取方法还包括:在步骤2)所述分离前,将所述植物粗提液进行浓缩处理的步骤。
- 根据权利要求1-3任一项所述的提取方法,其特征在于,步骤2)所述阳离子树脂选自强酸性阳离子交换树脂、弱酸性阳离子交换树脂和强碱性季铵型阳离子树脂中的一种或多种的组合;优选地,所述阳离子树脂选自732型强酸性苯乙烯系阳离子交换树脂、734型强酸性苯乙烯系阳离子交换树脂、002SC型强酸性苯乙烯系阳离子交换树脂、D001型大孔强酸性苯乙烯系阳离子交换树脂、D113型大孔弱酸性苯丙烯系阳离子交换树脂和D254型大孔强碱性季铵型阳离子交换树脂中的一种或多种的组合;优选地,所述阳离子树脂为732型强酸性苯乙烯系阳离子交换树脂、734型强酸性苯乙烯系阳离子交换树脂和D001型大孔强酸性苯乙烯系阳离子交换树脂;优选地,步骤2)中经阳离子树脂分离时,所述阳离子树脂与植物原材料投料的重量比为1:1-30,优选为1:1-25,更优选为1:2-20;优选地,步骤2)中所述阳离子树脂分离所用的洗脱剂为含有阳离子的溶液,所述洗脱剂中阳离子的浓度为0.04-5mol/L;优选地,步骤2)中阳离子树脂分离所用的洗脱剂重量为植物原材料投料重量的0.1-30倍,优选0.5-10倍。
- 根据权利要求1-4任一项所述的提取方法,其特征在于,步骤2)所述阴离子树脂为选自强碱性阴离子交换树脂、弱碱性阴离子交换树脂或弱酸性阴离子交换树脂中的一种或多种组合;优选地,所述阴离子树脂选自717型强碱性苯乙烯系阴离子交换树脂、711型强碱性苯乙烯系阴离子交换树脂、D201型大孔强碱性苯乙烯系阴离子交换树脂、D218型大孔强碱性丙烯酸系阴离子交换树脂、D301-G型大孔弱酸型苯乙烯系阴离子交换树脂和D301型大孔弱碱性苯乙烯系阴离子交换树脂中的一种或多种的组合;优选地,所述阴离子树脂为717型强碱性苯乙烯系阴离子交换树脂,D201型大孔强碱性苯乙烯系阴离子交换树脂和D218型大孔强碱性丙烯酸系阴离子交换树脂;优选地,步骤2)中经阴离子树脂分离时,所述阴离子树 脂与植物原材料投料的重量比为1:1-80,优选为1:1-64,更优选为1:1-32。
- 根据权利要求1-5任一项所述的提取方法,其特征在于,步骤4)中醇沉处理所用的乙醇与植物原材料投料的重量比为1:4-600,优选为1:20-300。
- 由权利要求1-6任一项所述的提取方法得到的植物提取物。
- 一种药物组合物,其特征在于,所述药物组合物包含权利要求7所述的植物提取物以及任选的药学上可接受的辅料;优选地,所述药物组合物的剂型包括:口服固体制剂和液体制剂;优选地,所述药物组合物的剂型包括:片剂、胶囊剂、口服溶液剂、口服乳剂、丸剂和颗粒剂。
- 权利要求7所述的植物提取物或者权利要求8所述的药物组合物在制备降糖药物中的应用。
- 权利要求7所述的植物提取物或者权利要求8所述的药物组合物在制备治疗糖耐量异常的药物中的应用。
- 权利要求7所述的植物提取物或者权利要求8所述的药物组合物在制备预防和/或治疗血糖异常相关疾病的药物中的应用。
- 权利要求7所述的植物提取物或者权利要求8所述的药物组合物在制备降脂药物中的应用。
- 权利要求7所述的植物提取物或者权利要求8所述的药物组合物在制备调节肠道菌群的药物中的应用。
- 一种食品、保健品或饮品,其特征在于,所述食品、保健品或饮品包含权利要求7所述的植物提取物。
- 权利要求7所述的植物提取物在制备食品、保健品或饮品中的应用。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20859199.0A EP4023239A4 (en) | 2019-08-27 | 2020-08-20 | PROCESS OF PLANT EXTRACTION |
KR1020227008595A KR102559310B1 (ko) | 2019-08-27 | 2020-08-20 | 식물 추출 방법 |
US17/638,011 US11779041B2 (en) | 2019-08-27 | 2020-08-20 | Plant extraction method |
AU2020336724A AU2020336724B2 (en) | 2019-08-27 | 2020-08-20 | Plant extraction method |
CA3149142A CA3149142C (en) | 2019-08-27 | 2020-08-20 | Plant extraction method |
JP2022512729A JP7309042B2 (ja) | 2019-08-27 | 2020-08-20 | 植物抽出方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910794907.2A CN110393738B (zh) | 2019-08-27 | 2019-08-27 | 一种植物提取方法 |
CN201910794907.2 | 2019-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021036896A1 true WO2021036896A1 (zh) | 2021-03-04 |
Family
ID=68329246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/110179 WO2021036896A1 (zh) | 2019-08-27 | 2020-08-20 | 一种植物提取方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11779041B2 (zh) |
EP (1) | EP4023239A4 (zh) |
JP (1) | JP7309042B2 (zh) |
KR (1) | KR102559310B1 (zh) |
CN (1) | CN110393738B (zh) |
AU (1) | AU2020336724B2 (zh) |
CA (1) | CA3149142C (zh) |
WO (1) | WO2021036896A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11779041B2 (en) | 2019-08-27 | 2023-10-10 | Beijing Wehand-Bio Pharmaceutical Co., Ltd | Plant extraction method |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111568949A (zh) * | 2020-06-03 | 2020-08-25 | 广西五和博澳药业有限公司 | 桑提取物在制备调节动物肠道菌群的药物中的用途 |
CN111568948A (zh) * | 2020-06-03 | 2020-08-25 | 北京五和博澳药业有限公司 | 桑提取物在制备改善胰岛功能药物中的应用 |
CN111658692A (zh) * | 2020-06-03 | 2020-09-15 | 北京五和博澳药业有限公司 | 桑提取物在制备治疗哺乳动物中糖脂代谢异常的药物中的用途 |
CN116850220A (zh) * | 2021-03-12 | 2023-10-10 | 北京五和博澳药业股份有限公司 | 桑提取物在制备减轻动物体重的药物中的应用 |
CN113143996B (zh) * | 2021-03-12 | 2022-10-04 | 北京五和博澳药业股份有限公司 | 桑提取物在制备治疗动物肠道炎症的组合物中的应用 |
CN113926218B (zh) * | 2021-11-15 | 2022-12-06 | 老蜂农生物科技集团有限公司 | 一种蜂胶乙醇提取物的生产工艺及蜂胶乙醇提取物 |
AU2023227026A1 (en) | 2022-03-04 | 2024-09-19 | Beijing Wehand-Bio Pharmaceutical Co., Ltd | Use of mulberry twig alkaloids in preparation of drug for treating polycystic ovarian syndrome |
CN116693703A (zh) * | 2023-07-12 | 2023-09-05 | 浦拉司科技(上海)有限责任公司 | 一种羟乙基纤维素去除金属离子的方法 |
CN117229338B (zh) * | 2023-11-13 | 2024-03-08 | 中泰(天津)生物科技有限公司 | 一种连翘叶综合提取连翘苷、连翘酯苷、芦丁、多糖的方法及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1611487A (zh) * | 2003-10-27 | 2005-05-04 | 成都华高天然产物有限责任公司 | 一种从葫芦巴中提取4-羟基异亮氨酸制品的新方法 |
CN1850166A (zh) * | 2006-03-08 | 2006-10-25 | 江苏大学 | 桑叶降血糖有效组分组合物及制备方法 |
CN102462817A (zh) * | 2010-11-19 | 2012-05-23 | 苏州宝泽堂医药科技有限公司 | 一种芦竹根生物碱的制备方法 |
CN104402801A (zh) * | 2014-10-31 | 2015-03-11 | 西南大学 | 分离dnj及制备dnj纳米混悬剂的方法 |
CN104844723A (zh) * | 2015-06-05 | 2015-08-19 | 云南金九地生物科技有限公司 | 一种铁皮石斛提取物的制备方法及应用 |
CN110393738A (zh) * | 2019-08-27 | 2019-11-01 | 北京五和博澳药业有限公司 | 一种植物提取方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1981814A (zh) * | 2005-12-15 | 2007-06-20 | 天津中新药业集团股份有限公司 | 一种桑叶提取物及其在制备糖尿病药物中的应用和制备方法 |
CN101129476B (zh) * | 2006-08-21 | 2013-07-24 | 中国医学科学院药物研究所 | 桑枝生物碱有效部位在制备降血糖药物中的应用 |
CN101412703B (zh) * | 2008-11-17 | 2011-06-01 | 江苏科技大学 | 一种联产桑叶黄酮、多糖和生物碱的复合提取工艺 |
CN102018766B (zh) | 2009-09-16 | 2013-03-06 | 博仲盛景医药技术(北京)有限公司 | 一种植物提取物、其提取方法和用途及含有这种提取物的组合物 |
CN104557675A (zh) * | 2014-12-08 | 2015-04-29 | 郑森衔 | 一种制备脱氧野尻霉素的方法 |
CN107362200B (zh) * | 2017-08-08 | 2021-01-01 | 南京中医药大学 | 一种从桑叶中提取分离生物碱和黄酮的方法 |
CN108552525B (zh) * | 2018-04-12 | 2021-07-13 | 广东省农业科学院蚕业与农产品加工研究所 | 一种降脂减肥功能食品 |
-
2019
- 2019-08-27 CN CN201910794907.2A patent/CN110393738B/zh active Active
-
2020
- 2020-08-20 WO PCT/CN2020/110179 patent/WO2021036896A1/zh active Application Filing
- 2020-08-20 US US17/638,011 patent/US11779041B2/en active Active
- 2020-08-20 CA CA3149142A patent/CA3149142C/en active Active
- 2020-08-20 JP JP2022512729A patent/JP7309042B2/ja active Active
- 2020-08-20 EP EP20859199.0A patent/EP4023239A4/en active Pending
- 2020-08-20 KR KR1020227008595A patent/KR102559310B1/ko active IP Right Grant
- 2020-08-20 AU AU2020336724A patent/AU2020336724B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1611487A (zh) * | 2003-10-27 | 2005-05-04 | 成都华高天然产物有限责任公司 | 一种从葫芦巴中提取4-羟基异亮氨酸制品的新方法 |
CN1850166A (zh) * | 2006-03-08 | 2006-10-25 | 江苏大学 | 桑叶降血糖有效组分组合物及制备方法 |
CN102462817A (zh) * | 2010-11-19 | 2012-05-23 | 苏州宝泽堂医药科技有限公司 | 一种芦竹根生物碱的制备方法 |
CN104402801A (zh) * | 2014-10-31 | 2015-03-11 | 西南大学 | 分离dnj及制备dnj纳米混悬剂的方法 |
CN104844723A (zh) * | 2015-06-05 | 2015-08-19 | 云南金九地生物科技有限公司 | 一种铁皮石斛提取物的制备方法及应用 |
CN110393738A (zh) * | 2019-08-27 | 2019-11-01 | 北京五和博澳药业有限公司 | 一种植物提取方法 |
Non-Patent Citations (8)
Title |
---|
"Chinese Pharmacopoeia", 2015 |
AIYING SHENZIYU ZHUWENLIANG ZHANG: "Study on the extraction process of water-soluble polysaccharides from mulberry leaves [J", ACTA SERICOLOGICA SINICA, vol. 30, no. 3, 2004, pages 277 - 279 |
LING LI-XIN, ZHANG GUO-FEN, FENG-MING CHEN: "Study on production technology of steviosin extraction from Stevia rebaudiana", SCIENCE AND TECHNOLOGY OF FOOD INDUSTRY, vol. 34, no. 6, 1 January 2013 (2013-01-01), pages 257 - 261, XP055786530, DOI: 10.13386/j.issn1002-0306.2013.06.029 * |
WANG XINTIAN, HUANG MINGYUE, LIANG SHUNWEI: "Pharmacological Study of Erycibe obtusifolia Benth Causing Pupil Constriction", JOURNAL OF NEW MEDICINE, vol. 09, no. 06, 1 June 1978 (1978-06-01), pages 279 - 280, XP009526420, ISSN: 0253-9802 * |
XINGJIE CHANGQIAN DING: "Forsythiaside A, Forsythin and changes of the bacteriostatic activities thereof in the preparation process of water extraction and alcohol precipitation of Forsythia [J", GUIDING JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, vol. 24, no. 9, 2018, pages 39 - 41 |
XUEJUN XIARENYUN WANGYULING LIU: "Determination of mulberry twig alkaloids by RP-HPLC with pre-column derivatization'' [J", CHINESE JOURNAL OF NEW DRUGS, vol. 17, no. 23, 2008, pages 2044 - 2047 |
ZHAI WENJUN, XU QING-MEI: "Research on the Divided Extraction of Rodgersia Aesculifolia-Batal and the Compound Formationã", JOURNAL OF SHAANXI INSTITUTE OF EDUCATION, vol. 23, no. 2, 1 May 2007 (2007-05-01), pages 62 - 64, XP055786532 * |
ZUOFA ZHANGJIE JINLIANGEN SHI: "Method for content determination of polysaccharide in Ramulus Mori", CHINA JOURNAL OF CHINESE MATERIA MEDICA [J, vol. 33, no. 4, 2018, pages 462 - 464 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11779041B2 (en) | 2019-08-27 | 2023-10-10 | Beijing Wehand-Bio Pharmaceutical Co., Ltd | Plant extraction method |
Also Published As
Publication number | Publication date |
---|---|
EP4023239A4 (en) | 2023-08-09 |
AU2020336724A1 (en) | 2022-04-07 |
US20220273014A1 (en) | 2022-09-01 |
KR102559310B1 (ko) | 2023-07-25 |
AU2020336724B2 (en) | 2024-09-19 |
KR20220053604A (ko) | 2022-04-29 |
CN110393738A (zh) | 2019-11-01 |
EP4023239A1 (en) | 2022-07-06 |
CA3149142A1 (en) | 2021-03-04 |
CA3149142C (en) | 2024-04-23 |
JP2022544422A (ja) | 2022-10-18 |
JP7309042B2 (ja) | 2023-07-14 |
US11779041B2 (en) | 2023-10-10 |
CN110393738B (zh) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021036896A1 (zh) | 一种植物提取方法 | |
WO2011079410A1 (zh) | 含向日葵提取物的药物组合物、制备方法及用途 | |
CA2486378A1 (en) | Preparation and application of total salvianolic acid | |
CN105707874A (zh) | 一种辣木叶压片及其制备方法 | |
CN111568948A (zh) | 桑提取物在制备改善胰岛功能药物中的应用 | |
CN107375430A (zh) | 一种具有防治糖尿病及并发症的姜黄素组合物 | |
CN101897942B (zh) | 温脾益肾,泄浊祛瘀的药物组合物的检测方法 | |
CN101333241B (zh) | 薯蓣皂苷的提取方法及其制剂与用途 | |
CN114366769B (zh) | 秦皮提取物与冰片的药物组合物、其制备方法和用途 | |
RU2818185C2 (ru) | Способ экстракции из растений | |
CN113144015A (zh) | 香连产物或其与抗生素联合在抗幽门螺杆菌药物中的应用 | |
CN110898170B (zh) | 一种治疗代谢综合征的中药组合物及其制剂 | |
CN106994142B (zh) | 一种枇杷提取物及其制备的降糖枇杷红茶提取物口含片 | |
CN1207028C (zh) | 膜与树脂联用制备一种中药固体制剂的方法 | |
CN105362454A (zh) | 一种具有辅助降糖功能的组合物及其制备方法和用途 | |
CN100450496C (zh) | 一种治疗心脑血管疾病的三七和红花复方制剂 | |
CN107753551B (zh) | 一种具有降血压功能的组合物及其制备方法 | |
CN106619972A (zh) | 蝙蝠蛾被毛孢菌丝体粉降血糖胶囊、其制备方法及用途 | |
WO2016110168A1 (zh) | 20(R)-人参皂苷Rg3在制备缓解或/和治疗糖尿病药物或保健品中的应用及药物 | |
CN104547498A (zh) | 一种中药组合物的新用途 | |
JP2024509199A (ja) | 動物の体重減少薬を製造するための桑抽出物の使用 | |
UA145468U (uk) | Збір лікарських рослин № 3 для профілактики та лікування цукрового діабету 2 типу | |
CN102475781B (zh) | 一种治疗原发性高血压的中药组合物的制备方法 | |
CN102475778B (zh) | 一种治疗原发性高血压的中药组合物的制备方法 | |
CN102475782B (zh) | 一种治疗原发性高血压的中药组合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20859199 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022512729 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3149142 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: P6000333/2022 Country of ref document: AE Ref document number: 140050140003009194 Country of ref document: IR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20227008595 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020859199 Country of ref document: EP Effective date: 20220328 |
|
ENP | Entry into the national phase |
Ref document number: 2020336724 Country of ref document: AU Date of ref document: 20200820 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522431745 Country of ref document: SA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522431745 Country of ref document: SA |